Is Acemini on Medicare? Does Sidai Pharmacy sell it?

Asciminib (Asciminib) is a targeted therapy drug mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML). The drug has a unique mechanism of action. As a selective kinase inhibitor, it can effectively target the BCR-ABL1 fusion protein, especially when traditional tyrosine kinase inhibitors (TKIs) are ineffective or resistant.

In most patients with chronic myelogenous leukemia (CML), disease progression is driven primarily by a translocation on the Philadelphia chromosome that creates the oncogenic fusion gene BCR-ABL1 between the BCR and ABL1 genes. This fusion gene produces a synthetic fusion protein, BCR-ABL1, which exhibits elevated tyrosine kinase and transforming activity that promotes CML proliferation.

Aximini is particularly indicated for patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia, including those first diagnosed in the chronic phase (CP), and those who have received unsatisfactory results from previous treatments. In addition, Asiminib can also effectively target Ph+CML patients in CP with T315I mutation. This mutation usually leads to the failure of standard TKIs treatment. Therefore, the launch of Asiminib provides a new treatment option for these patients.

As for whether Asiminib has been included in the medical insurance, the current situation is that the original drug Asiminib is not on the domestic market, so there is no way to enter the national medical insurance scope. Patients and their families should consult the responsible doctor and relevant medical insurance departments when seeking medical treatment to obtain the latest information and help. As for the sales of Aceminid in fourth-generation pharmacies, since it is a prescription drug to treat a specific disease, it is not usually widely sold in regular pharmacies. Patients need to go to a hospital and get a prescription to get this drug.